摘要
目的探讨抗癌平丸联合曲妥珠单抗及化疗对HER2阳性晚期胃癌患者近期疗效及远期疗效的影响。方法将98例HER2阳性晚期胃癌患者作为研究对象,将其随机分为观察组和对照组,每组49例。对照组给予曲妥珠单抗及m FOLFOX6方案化疗,观察组则在对照组基础上另口服给予抗癌平丸。治疗后,观察两组临床疗效。治疗后,对两组进行为期3年的随访,观察两组总生存时间(OS)、无疾病进展生存时间(PFS)、1年生存率及3年生存率。治疗期间,观察两组毒副作用,主要包括心脏毒性、胃肠道反应、肝毒性、肾毒性、骨髓抑制及神经毒性等。结果治疗后,观察组有效率及控制率均显著高于对照组(P <0. 05)。治疗后,观察组PFS、OS、1年生存率及3年生存率均明显高于对照组(P <0. 05)。治疗期间,观察组心脏毒性、胃肠道反应、肝毒性、肾毒性、骨髓抑制及神经毒性发生率均明显低于对照组(P <0. 05)。结论抗癌平丸联合曲妥珠单抗及化疗对HER2阳性晚期胃癌疗效较好,值得进行深入研究。
Objective To observe the clinical effects of kangaipingwan and trastuzumab with chemotherapy in short-term effects and long-term effects in patients with HER2 positive Advanced gastric cancer.Methods 98 cases of HER2 positive advanced gastric cancer patients in our hospital were randomly divided observation group(49 cases)and control group(49 cases).The control group was treated with mFOLFOX6 method and trastuzumab,while kangaipingwan was given in the observation group.After the treatment,the short-term effects were observed in the 2 groups.The long-term effects were performed;the 1-year survival rate,3-years survival rate,overall survival(OS)and progression-freely-survival(PFS)were observed in the two groups.During the treatment,the rates of cardiac toxicity,gastrointestinal reaction,hepatotoxicity,nephrotoxicity,bone marrow suppression and neurotoxicity were observed in the two groups.Results The efficiency and control rates in observation group were significantly higher than the control group(P<0.05).During the treatment,the rates of cardiac toxicity,gastrointestinal reaction,hepatotoxicity,nephrotoxicity,bone marrow suppression and neurotoxicity were significantly lower in the observation group than control group(P<0.05).The long-term effects shown,the 1-year survival rate,3-years survival rate,PFS and OS in the observation group were significantly longer than control group(P<0.05).Conclusion Kangaipingwan and trastuzumab with chemotherapy in the treatment of HER2 positive advanced gastric cancer has a good effect,worth to the next study.
作者
陈福敏
罗君
杜茂福
张欣平
CHEN Fumin;LUO Jun;DU Maofu(Nanchong Central Hospital,Nanchong,637000)
出处
《实用癌症杂志》
2019年第2期264-266,284,共4页
The Practical Journal of Cancer
关键词
抗癌平丸
曲妥珠单抗
化疗
HER2阳性
晚期胃癌
Kangaipingwan
Trastuzumab
Chemotherapy
HER2 positive
Advanced gastric cancer
